Gerco Den Hartog
Overview
Explore the profile of Gerco Den Hartog including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
1491
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Den Hartog G, Andeweg S, Hoeve C, Smits G, Voordouw B, Eggink D, et al.
Sci Rep
. 2023 Oct;
13(1):18394.
PMID: 37884642
Immunity induced by vaccination and infection, referred to as hybrid immunity, provides better protection against SARS-CoV-2 infections compared to immunity induced by vaccinations alone. To assess the development of hybrid...
22.
de Boer P, van de Kassteele J, Vos E, van Asten L, Dongelmans D, van Gageldonk-Lafeber A, et al.
Influenza Other Respir Viruses
. 2023 Aug;
17(8):e13174.
PMID: 37621921
Background: The severity of Severe Acute Respiratory Syndrome Coronavirus 2 infection varies with age and time. Here, we quantify how age-specific risks of hospitalization, intensive care unit (ICU) admission, and...
23.
de Gier B, Huiberts A, Hoeve C, Den Hartog G, van Werkhoven H, van Binnendijk R, et al.
Nat Commun
. 2023 Aug;
14(1):4793.
PMID: 37558656
An increasing proportion of the population has acquired immunity through COVID-19 vaccination and previous SARS-CoV-2 infection, i.e., hybrid immunity, possibly affecting the risk of new infection. We aim to estimate...
24.
Hofsink Q, Haggenburg S, Lissenberg-Witte B, Broers A, van Doesum J, van Binnendijk R, et al.
EClinicalMedicine
. 2023 Jun;
61:102040.
PMID: 37337616
Background: Patients with haematological malignancies have impaired antibody responses to SARS-CoV-2 vaccination. We aimed to investigate whether a fourth mRNA COVID-19 vaccination improved antibody quantity and quality. Methods: In this...
25.
Huiberts A, de Gier B, Hoeve C, de Melker H, Hahne S, Den Hartog G, et al.
Int J Infect Dis
. 2023 Apr;
133:36-42.
PMID: 37086863
Objectives: We estimated vaccine effectiveness (VE) of primary and booster vaccinations against SARS-CoV-2 infection overall and in four risk groups defined by age and medical risk condition during the Delta...
26.
Huiberts A, de Gier B, Hoeve C, de Melker H, Hahne S, Den Hartog G, et al.
Euro Surveill
. 2023 Feb;
28(7).
PMID: 36795500
We used data of 32,542 prospective cohort study participants who previously received primary and one or two monovalent booster COVID-19 vaccinations. Between 26 September and 19 December 2022, relative effectiveness...
27.
Den Hartog G, van Kasteren P, Schepp R, Teirlinck A, van der Klis F, Van Binnendijk R
Lancet Infect Dis
. 2022 Dec;
23(1):23-25.
PMID: 36463892
No abstract available.
28.
Kho M, Messchendorp A, Frolke S, Imhof C, Koomen V, Malahe S, et al.
Lancet Infect Dis
. 2022 Nov;
23(3):307-319.
PMID: 36354032
Background: An urgent need exists to improve the suboptimal COVID-19 vaccine response in kidney transplant recipients (KTRs). We aimed to compare three alternative strategies with a control single dose mRNA-1273...
29.
Roozen G, Prins M, van Binnendijk R, Den Hartog G, Kuiper V, Prins C, et al.
Ann Intern Med
. 2022 Oct;
175(12):1771-1774.
PMID: 36279543
No abstract available.
30.
van den Hoogen L, Boer M, Postema A, de Rond L, de Zeeuw-Brouwer M, Pronk I, et al.
Vaccines (Basel)
. 2022 Sep;
10(9).
PMID: 36146557
Vaccine-induced protection against severe COVID-19, hospitalization, and death is of the utmost importance, especially in the elderly. However, limited data are available on humoral immune responses following COVID-19 vaccination in...